Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.61 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.61 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.61 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | FAP | Q12884 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4550698 | 1.00 | DPP4 (0.61) | DPP4DPP8DPP7DPP9ACE | |
| Hydrochloric Acid SCHEMBL4399414 | 0.99 | DPP4 (0.61) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL8345171 | 0.90 | DPP4 (0.66) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL4387254 | 0.86 | DPP4 (0.56) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL4392074 | 0.82 | DPP4 (0.44) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL4400632 | 0.77 | DPP4 (0.60) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL5228197 | 0.76 | DPP4 (1.00) | DPP4DPP8DPP7DPP9ACE | |
| Hydrochloric Acid SCHEMBL4399397 | 0.76 | DPP4 (0.59) | DPP4DPP8DPP7DPP9 | |
| Hydrochloric Acid SCHEMBL1842316 | 0.76 | DPP4 (0.98) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL16161427 | 0.75 | DPP4 (0.72) | DPP4DPP8DPP7DPP9ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554256-B1 | PIPERIDINO PYRIMIDINE DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK & CO INC (US) | 2009-12-09 | — | — | EP | disclosed |
| US-7208498-B2 | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes | MERCK & CO., INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208498-B2 | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes | MERCK & CO., INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208498-B2 | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes | MERCK & CO., INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060040963-A1 | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| WO-2004007468-A1 | PIPERIDINO PYRIMIDINE DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK & CO., INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040963-A1 | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.